Lexotan (Bromazepam)

Bromazepam acts as a positive allosteric modulator at the GABA‑A receptor. By binding to a specific site on the receptor complex, it enhances the effect of the inhibitory neurotransmitter GABA, increasing chloride ion flow into neurons. This reduces neuronal excitability and produces anxiolytic, sedative, and muscle‑relaxant effects.

The appropriate dose of Lexotan is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, response to therapy, and other medications. Dosage regimens are personalized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for bromazepam in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss alternatives and closely monitor any pregnant or nursing patient who requires treatment.

To request Lexotan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lexotan (bromazepam) is similar to other benzodiazepines such as diazepam or lorazepam in providing anxiolytic and sedative effects. Compared with diazepam, bromazepam has a shorter half‑life and may be preferred when a quicker offset of action is desired. Choice of agent depends on clinical context, duration of therapy, and individual patient factors.

Lexotan should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight. Do not store in bathrooms or near kitchen appliances. Keep out of reach of children and unused medication should be disposed of according to local regulations.

Lexotan is administered orally. The tablet should be swallowed whole with a glass of water and may be taken with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided by their healthcare professional and avoid crushing or chewing the tablet unless specifically instructed.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, and the potential for dependence, tolerance and withdrawal symptoms after prolonged use. Severe allergic reactions and profound sedation are also possible. Patients should be monitored closely for these events, particularly during dose adjustments.

Lexotan is contraindicated in individuals with known hypersensitivity to bromazepam or any benzodiazepine, severe respiratory insufficiency, acute narrow‑angle glaucoma, and in patients who are currently abusing alcohol or other depressant substances. Caution is also advised for the elderly, patients with hepatic impairment, and those with a history of substance dependence.